Fortis Healthcare executed a major block trade on the National Stock Exchange (NSE), marking significant institutional trading activity in the healthcare sector. The transaction involved a substantial volume of shares at a premium price point.

Block Trade Details

The block trade encompassed 419,265 shares of Fortis Healthcare, executed at ₹885.10 per share. This pricing resulted in a total transaction value of ₹37.11 crores, indicating strong institutional interest in the healthcare company's stock.

Market Significance

Block trades typically involve large institutional investors and represent significant capital movements in the market. The execution of this trade at ₹885.10 per share demonstrates the price discovery mechanism for large volume transactions in Fortis Healthcare's stock.

The transaction size of ₹37.11 crores reflects substantial institutional participation, which often indicates confidence in the company's fundamentals and growth prospects among large investors. Such block trades are executed outside the regular market hours to minimize impact on stock price volatility.

Fortis Healthcare Limited , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, with significant growth in both revenue and profitability.

Strong Revenue Growth

The company's consolidated revenue for Q2 FY26 stood at INR2,331.00 crores, marking a 17.3% increase compared to the same period last year. This growth was primarily driven by the hospital segment, which saw a 19.3% year-on-year increase in revenue to INR1,974.00 crores. The diagnostic business also contributed positively, with a 7.1% growth in net revenue to INR357.00 crores.

Improved Profitability

Fortis Healthcare's consolidated operating EBITDA surged by 28% to INR556.00 crores, with the EBITDA margin expanding to 23.9% from 21.9% in Q2 FY25. The hospital business reported an operating EBITDA of INR452.00 crores, showing a 150 basis points improvement in margin to 22.9%. The company's profit after tax before exceptional items increased by 20.7% to INR305.00 crores.

Key Operational Metrics

Expansion and Strategic Initiatives

Fortis Healthcare has been actively pursuing growth opportunities:

• Entered a 15-year lease agreement for a 200-bed multi-specialty hospital in Greater Noida.
• Signed an O&M agreement for a 550-bed greenfield super specialty hospital in Lucknow.
• Acquired Shrimann Super Speciality Hospital in Jalandhar, adding 190 operational beds.
• Entered into an O&M agreement with Gleneagles India to manage five hospitals and a clinic.
• Added 550 operational beds in H1 FY26 through various initiatives.

Diagnostic Business Performance

The diagnostic arm, Agilus Diagnostics, reported a 7.3% increase in gross revenue to INR400.00 crores. The operating EBITDA margin for this segment improved to 26.1% from 21.5% in Q2 FY25.

Dr. Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, commented on the results: "We continue to witness a healthy growth momentum in Q2 FY26 and H1 of FY26. Both our business segments, Hospitals and Diagnostics, continue to perform well both in terms of revenue and margins."

With these positive results and ongoing expansion initiatives, Fortis Healthcare continues to strengthen its position in the Indian healthcare sector, focusing on both organic growth and strategic acquisitions to enhance its service offerings and market presence.